Eur Rev Med Pharmacol Sci 2023; 27 (20): 9987-10000
DOI: 10.26355/eurrev_202310_34179

Clinical research advances of CFHR5 nephropathy: a recent review

Z.-G. Fei, K. Zhen, F.-J. Zhang, P.-Y. Liu, H.-Y. Xu, H.-H. Chen

College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China. 370871674@qq.com


CFHR5 nephropathy is a type of clinical C3 glomerulopathy, which is a monogenic genetic disease caused by the internal replication of CFHR5 gene, a protein related to the complement regulatory factor H family. The disease seems to be prevalent only in people of Greek Cypriot descent. Because of the special variation of the internal replication of exon 2 and exon 3 of CFHR5 protein in the occurrence of disease, it has had a serious impact on local residents. At present, the mechanism of glomerular damage caused by CFHR5 protein mutations is still unclear. The purpose of this article is to review the clinical research advances of this disease in the past 10 years, including the study of mutant genes, the analysis of mutant proteins and the role of alternative pathways in glomerular injury. It covers the progress in diagnosis and clinical treatment of the disease and looks forward to the future development prospects of its treatment. It is hoped that the recent results will be summarized for the follow-up in-depth study of CFHR5 nephropathy.

Free PDF Download

To cite this article

Z.-G. Fei, K. Zhen, F.-J. Zhang, P.-Y. Liu, H.-Y. Xu, H.-H. Chen
Clinical research advances of CFHR5 nephropathy: a recent review

Eur Rev Med Pharmacol Sci
Year: 2023
Vol. 27 - N. 20
Pages: 9987-10000
DOI: 10.26355/eurrev_202310_34179